(2E)-N-(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
| Title | Journal |
|---|---|
| Adaptive Randomization of Neratinib in Early Breast Cancer. | The New England journal of medicine 20160707 |
| A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | Toxicological sciences : an official journal of the Society of Toxicology 20131101 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Dual blockade of HER2 - twice as good or twice as toxic? | Clinical oncology (Royal College of Radiologists (Great Britain)) 20121101 |
| New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? | Cancer treatment reviews 20120801 |
| Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. | Biochemical pharmacology 20120801 |
| Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications. | International journal of cancer 20120701 |
| A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor. | Cancer chemotherapy and pharmacology 20120701 |
| Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. | Molecular pharmacology 20120701 |
| Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy. | International journal of oncology 20120601 |
| Neratinib (HKI-272) in the treatment of breast cancer. | Future oncology (London, England) 20120601 |
| Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study. | Japanese journal of clinical oncology 20120401 |
| A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers. | Molecular bioSystems 20120401 |
| Preformulation stability study of the EGFR inhibitor HKI-272 (Neratinib) and mechanism of degradation. | Drug development and industrial pharmacy 20120301 |
| Comprehensive analysis of kinase inhibitor selectivity. | Nature biotechnology 20111030 |
| Beyond trastuzumab: new treatment options for HER2-positive breast cancer. | Breast (Edinburgh, Scotland) 20111001 |
| A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments. | Molecular bioSystems 20110601 |
| The search for improved systemic therapy of non-small cell lung cancer--what are today's options? | Lung cancer (Amsterdam, Netherlands) 20110601 |
| Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. | British journal of clinical pharmacology 20110401 |
| Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. | Journal of medicinal chemistry 20110310 |
| [Novel target therapies used in breast cancer management]. | Voprosy onkologii 20110101 |
| Irreversible EGFR inhibitor EKB-569 targets low-LET γ-radiation-triggered rel orchestration and potentiates cell death in squamous cell carcinoma. | PloS one 20110101 |
| Reversible covalent binding of neratinib to human serum albumin in vitro. | Drug metabolism letters 20101201 |
| Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. | Chemistry & biology 20101124 |
| A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100801 |
| Characterization of HKI-272 covalent binding to human serum albumin. | Drug metabolism and disposition: the biological fate of chemicals 20100701 |
| Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100620 |
| The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. | Cancer investigation 20100501 |
| Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100310 |
| [Management of metastatic HER2-positive breast cancer: present and future]. | Bulletin du cancer 20100301 |
| Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. | Cancer treatment reviews 20091201 |
| [New development in the treatment of breast cancer. II. Future anti-HER2 therapy]. | Gan to kagaku ryoho. Cancer & chemotherapy 20091201 |
| Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. | Expert opinion on investigational drugs 20091101 |
| A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090401 |
| Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors. | Bioorganic & medicinal chemistry letters 20090101 |
| The development of HKI-272 and related compounds for the treatment of cancer. | Archiv der Pharmazie 20080801 |
| Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080601 |
| The T790M 'gatekeeper' mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. | Molecular cancer therapeutics 20080401 |
| Enzyme replacement therapy for Gaucher's disease in patient treated for non-small cell lung cancer. | Anticancer research 20080101 |
| HKI-272 in non small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070801 |
| The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. | Oncogene 20070726 |
| Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. | Cancer cell 20070701 |
| Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. | Bioorganic & medicinal chemistry 20070601 |
| Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. | Cancer biology & therapy 20070501 |
| Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. | The oncologist 20070301 |
| Pharmacology of epidermal growth factor inhibitors. | The International journal of biological markers 20070101 |
| Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. | Cancer research 20060701 |
| The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. | Cancer cell 20060601 |
| EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. | Cancer cell 20060601 |
| Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. | Journal of medicinal chemistry 20050224 |
| Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. | Cancer research 20040601 |